<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504282</url>
  </required_header>
  <id_info>
    <org_study_id>8901</org_study_id>
    <nct_id>NCT01504282</nct_id>
  </id_info>
  <brief_title>Mitomycin-c Application for PRK</brief_title>
  <official_title>Mitomycin-c Application for Photorefractive Keratectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of 5 seconds mitomycin-C (MMC) application during
      photorefractive keratectomy (PRK) for patients with low myopia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central corneal endothelial cell density (ECD) 6 months after the PRK</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>90</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>MMC group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One eye of each patient was randomly assigned to receive intraoperative topical 0.02% MMC for 5 seconds.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BSS group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One eye of each patient was randomly assigned to receive balanced salt solution (BSS) with the same manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitomycin-C</intervention_name>
    <arm_group_label>MMC group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>balanced salt solution (BSS)</description>
    <arm_group_label>BSS group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The inclusion criteria was ablation depth less than 65 Âµm,

          -  a stable refractive error for at least 1 year

          -  corrected distance visual acuity (CDVA) of 0.1 LogMAR or better.

        Exclusion Criteria:

          -  Patients with keratoconus suspect,

          -  excessive dry eyes,

          -  impaired wound healing processes,

          -  lenticular changes,

          -  corneal dystrophy,

          -  history of ocular surgery,

          -  anterior or posterior uveitis,

          -  glaucoma and retinal diseases were excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2012</study_first_submitted>
  <study_first_submitted_qc>January 4, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2012</study_first_posted>
  <last_update_submitted>January 4, 2012</last_update_submitted>
  <last_update_submitted_qc>January 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 5, 2012</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

